Literature DB >> 4038613

Catabolism of human tissue plasminogen activator in mice.

H E Fuchs, H Berger, S V Pizzo.   

Abstract

The catabolism of human tissue plasminogen activator (t-PA) was studied in mice. The clearance of t-PA labeled with iodine 125 was rapid (t1/2). The clearance of phenylmethylsulfonyl-125I-t-PA, which is active site-inhibited, was identical to the active enzyme. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) demonstrated that the vast majority of 125I-t-PA injected into the circulation was present as free enzyme and not in a complex with inhibitors. The clearance of 125I-t-PA was unaltered by large molar excesses of several ligands of known clearance specificities, including macroalbumin, asialoorosomucoid, and diisopropylphosphorylthrombin and was also not altered in the presence of a 1,000-fold molar excess of unlabeled t-PA. Organ distribution studies demonstrated that the early rapid clearance of 125I-t-PA occurred in hepatocytes, followed by a later renal phase of clearance. The clearance of 125I-urokinase (UK) also was studied and was very similar in all aspects to the clearance of 125I-t-PA. These results suggest that both t-PA and UK are cleared from the circulation by unique nonsaturable processes localized in the liver that are independent of the proteinase active site.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4038613

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

1.  Clearance of the heavy and light polypeptide chains of human tissue-type plasminogen activator in rats.

Authors:  D C Rijken; J J Emeis
Journal:  Biochem J       Date:  1986-09-15       Impact factor: 3.857

Review 2.  Translational initiatives in thrombolytic therapy.

Authors:  Melvin E Klegerman
Journal:  Front Med       Date:  2017-03-02       Impact factor: 4.592

3.  Autonomous functions of structural domains on human tissue-type plasminogen activator.

Authors:  A J van Zonneveld; H Veerman; H Pannekoek
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

4.  Characterization of indium-111 labeled recombinant tissue plasminogen activator for the imaging of thrombi.

Authors:  D J Hnatowich; F Virzi; P W Doherty; J Wilson; J Rosa; J E Ansell
Journal:  Eur J Nucl Med       Date:  1987

Review 5.  Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

Authors:  D Collen; H R Lijnen; P A Todd; K L Goa
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

6.  Tissue-type plasminogen activator regulates macrophage activation and innate immunity.

Authors:  Elisabetta Mantuano; Pardis Azmoon; Coralie Brifault; Michael A Banki; Andrew S Gilder; Wendy M Campana; Steven L Gonias
Journal:  Blood       Date:  2017-07-06       Impact factor: 22.113

7.  In vivo distribution of Tc-99m labeled recombinant tissue-type plasminogen activator in control and thrombus-bearing rats.

Authors:  E Tsukamoto
Journal:  Ann Nucl Med       Date:  1992-08       Impact factor: 2.668

Review 8.  New strategies in the development of thrombolytic agents.

Authors:  H R Lijnen; D Collen
Journal:  Blut       Date:  1988-10

9.  Random PCR mutagenesis screening of secreted proteins by direct expression in mammalian cells.

Authors:  G C Rice; D V Goeddel; G Cachianes; J Woronicz; E Y Chen; S R Williams; D W Leung
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

10.  39-kD protein inhibits tissue-type plasminogen activator clearance in vivo.

Authors:  I Warshawsky; G Bu; A L Schwartz
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.